Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tumor profiling platform for immunotherapy response prediction, today announced a Series B-2 funding of $40 million.
The equity round included participation from existing investors including Northpond Ventures, ARCH Venture Partners, the State of Wisconsin Investment Board, Tao Capital Partners, Sands Capital, Venture Investors Health Fund, among others.
Read More – fomo Raises $17M in Series A Funding
The capital raised will support the launch and commercialization of the proprietary Elephas Live™ Platform as a laboratory developed test (LDT) in 2026. The Elephas Live Platform is designed to functionally profile ex vivo live tumor biopsies. By protecting the native tumor microenvironment and using a novel method to address tumor heterogeneity, the technology allows for prediction of immunotherapy response.
“This financing milestone underscores the strong investor confidence in the promise of Elephas and our shared mission to improve the lives of those affected by cancer,” said Maneesh Arora, Elephas founder and CEO. “We have made incredible progress this year and have strong momentum heading into 2026. This funding achievement will drive our next stage of growth and advance our commercialization strategy.”
Earlier this fall, Elephas welcomed Jérôme Galon, Ph.D., to the Company’s expanding Scientific Advisory Board. Dr. Galon and fellow Elephas advisory board member Janis Taube, M.D., will be joining Elephas at the upcoming Societies for the Immunotherapy in Cancer (SITC) Annual Meeting on November 8, 2025, in National Harbor, MD for a symposium discussing the improved prediction of immunotherapy response.
Read More – Braveheart Bio Raises $185M in Series A Funding
